{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,10]],"date-time":"2026-05-10T11:21:34Z","timestamp":1778412094465,"version":"3.51.4"},"reference-count":25,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2013,2,9]],"date-time":"2013-02-09T00:00:00Z","timestamp":1360368000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["American J Hematol"],"published-print":{"date-parts":[[2013,3]]},"DOI":"10.1002\/ajh.23399","type":"journal-article","created":{"date-parts":[[2013,1,24]],"date-time":"2013-01-24T11:55:58Z","timestamp":1359028558000},"page":"163-165","source":"Crossref","is-referenced-by-count":13,"title":["Competing for the treasure in exceptions"],"prefix":"10.1002","volume":"88","author":[{"given":"Timothy M.","family":"Cox","sequence":"first","affiliation":[{"name":"Department of Medicine University of Cambridge Cambridge United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2013,2,9]]},"reference":[{"key":"e_1_2_2_2_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrd3160"},{"key":"e_1_2_2_3_1","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.med.57.110104.115650"},{"key":"e_1_2_2_4_1","first-page":"81","article-title":"Imiglucerase in the treatment of Gaucher disease: A history and perspective","volume":"6","author":"Deegan PB","year":"2012","journal-title":"Drug Des Devel Ther"},{"key":"e_1_2_2_5_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199105233242104"},{"issue":"1","key":"e_1_2_2_6_1","first-page":"124","article-title":"Gene transfer and bone marrow transplantation with special reference to Gaucher's disease","volume":"11","author":"Karlsson S","year":"1993","journal-title":"Bone Marrow Transplant"},{"key":"e_1_2_2_7_1","first-page":"547","article-title":"Receptor\u2010mediated uptake of lysosomal enzymes","volume":"23","author":"Sly WS","year":"1978","journal-title":"Prog Clin Biol Res"},{"key":"e_1_2_2_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/0304-4165(81)90474-8"},{"key":"e_1_2_2_9_1","unstructured":"FriedmanB HayesM.Enhanced in vivo uptake of glucocerebrosidase. US Patent5549892 1996."},{"key":"e_1_2_2_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(96)04451-0"},{"key":"e_1_2_2_11_1","article-title":"Long\u2010term clinical outcomes in type 1 Gaucher disease following 10 years of imiglucerase treatment","author":"Weinreb NJ","journal-title":"J Inherit Metab Dis"},{"key":"e_1_2_2_12_1","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0b013e3182057be4"},{"key":"e_1_2_2_13_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrd3445"},{"key":"e_1_2_2_14_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.c6471"},{"key":"e_1_2_2_15_1","doi-asserted-by":"publisher","DOI":"10.1023\/A:1025902113005"},{"key":"e_1_2_2_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcmd.2009.09.006"},{"key":"e_1_2_2_17_1","article-title":"Safety and efficacy of velaglucerase alfa in Gaucher disease type 1 patients previously treated with imiglucerase","author":"Zimran A","journal-title":"Am J Hematol"},{"key":"e_1_2_2_18_1","article-title":"Enzyme replacement therapy with velaglucerase alfa in Gaucher disease: Results from a randomized, double\u2010blind, multinational, Phase 3 study","author":"Gonzalez DE","journal-title":"Am J Hematol"},{"key":"e_1_2_2_19_1","article-title":"Velaglucerase alfa enzyme replacement therapy compared with imiglucerase in patients with Gaucher disease","author":"Ben Turkia H","journal-title":"Am J Hematol"},{"key":"e_1_2_2_20_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrd3311"},{"key":"e_1_2_2_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0021-9258(18)55439-9"},{"key":"e_1_2_2_22_1","doi-asserted-by":"publisher","DOI":"10.1093\/glycob\/cwp138"},{"key":"e_1_2_2_23_1","first-page":"472","article-title":"Velaglucerase alfa, a human recombinant glucocerebrosidase enzyme replacement therapy for type 1 Gaucher disease","volume":"11","author":"Pastores GM","year":"2010","journal-title":"Curr Opin Investig Drugs"},{"key":"e_1_2_2_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jim.2011.07.020"},{"key":"e_1_2_2_25_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1467-7652.2007.00263.x"},{"key":"e_1_2_2_26_1","first-page":"1169","article-title":"Eliglustat tartrate, an orally active glucocerebroside synthase inhibitor for the potential treatment of Gaucher disease and other lysosomal storage diseases","volume":"11","author":"Cox TM","year":"2010","journal-title":"Curr Opin Investig Drugs"}],"container-title":["American Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fajh.23399","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ajh.23399","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,16]],"date-time":"2023-10-16T09:26:18Z","timestamp":1697448378000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/ajh.23399"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,2,9]]},"references-count":25,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2013,3]]}},"alternative-id":["10.1002\/ajh.23399"],"URL":"https:\/\/doi.org\/10.1002\/ajh.23399","archive":["Portico"],"relation":{},"ISSN":["0361-8609","1096-8652"],"issn-type":[{"value":"0361-8609","type":"print"},{"value":"1096-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,2,9]]}}}